|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: B3GNTL1 |
Gene summary for B3GNTL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | B3GNTL1 | Gene ID | 146712 |
| Gene name | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase like 1 | |
| Gene Alias | 3-Gn-T8 | |
| Cytomap | 17q25.3 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | A0A024R8X6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 146712 | B3GNTL1 | HCC1_Meng | Human | Liver | HCC | 6.01e-24 | 3.74e-02 | 0.0246 |
| 146712 | B3GNTL1 | HCC2_Meng | Human | Liver | HCC | 3.59e-05 | 3.88e-02 | 0.0107 |
| 146712 | B3GNTL1 | S014 | Human | Liver | HCC | 1.25e-02 | 1.52e-01 | 0.2254 |
| 146712 | B3GNTL1 | S015 | Human | Liver | HCC | 3.96e-05 | 1.38e-01 | 0.2375 |
| 146712 | B3GNTL1 | S027 | Human | Liver | HCC | 5.82e-04 | 4.17e-01 | 0.2446 |
| 146712 | B3GNTL1 | S028 | Human | Liver | HCC | 2.42e-15 | 5.26e-01 | 0.2503 |
| 146712 | B3GNTL1 | S029 | Human | Liver | HCC | 8.93e-23 | 6.09e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| B3GNTL1 | SNV | Missense_Mutation | novel | c.997N>A | p.Val333Met | p.V333M | Q67FW5 | protein_coding | tolerated(0.07) | probably_damaging(0.935) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| B3GNTL1 | SNV | Missense_Mutation | c.779G>A | p.Arg260His | p.R260H | Q67FW5 | protein_coding | tolerated(1) | benign(0) | TCGA-CM-6161-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| B3GNTL1 | SNV | Missense_Mutation | c.82N>G | p.Asn28Asp | p.N28D | Q67FW5 | protein_coding | deleterious(0.05) | probably_damaging(0.999) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| B3GNTL1 | SNV | Missense_Mutation | novel | c.147N>A | p.Met49Ile | p.M49I | Q67FW5 | protein_coding | tolerated(0.43) | benign(0.001) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| B3GNTL1 | SNV | Missense_Mutation | rs111333063 | c.130G>T | p.Asp44Tyr | p.D44Y | Q67FW5 | protein_coding | deleterious(0) | probably_damaging(0.925) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| B3GNTL1 | SNV | Missense_Mutation | novel | c.961C>T | p.His321Tyr | p.H321Y | Q67FW5 | protein_coding | deleterious(0.05) | possibly_damaging(0.463) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| B3GNTL1 | SNV | Missense_Mutation | rs769610364 | c.341N>T | p.Ser114Leu | p.S114L | Q67FW5 | protein_coding | tolerated(0.06) | possibly_damaging(0.657) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| B3GNTL1 | SNV | Missense_Mutation | novel | c.749N>C | p.Val250Ala | p.V250A | Q67FW5 | protein_coding | deleterious(0.03) | benign(0.061) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| B3GNTL1 | SNV | Missense_Mutation | novel | c.787N>A | p.Ala263Thr | p.A263T | Q67FW5 | protein_coding | tolerated(0.39) | benign(0.001) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| B3GNTL1 | SNV | Missense_Mutation | rs776592296 | c.718N>A | p.Val240Ile | p.V240I | Q67FW5 | protein_coding | tolerated(0.53) | benign(0.014) | TCGA-EO-A22S-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |